Anneliz de Leeuw, MD, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the shortfalls of radiotherapy for head and neck cancer. There is currently no differentiation in the radiotherapy dose that head and neck cancer patients receive. It is therefore important to distinguish between patients who are able to receive either dose de-escalation or escalation, to enable optimal locoregional control with minimal toxicity risks. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.